Mannkind reported $22.1M in Selling and Administration Expenses for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Adma Biologics ADMA:US USD 17.75M 1.86M
Biocryst Pharmaceuticals BCRX:US USD 50.15M 13.23M
Dynavax Technologies DVAX:US USD 30.38M 1.22M
Eli Lilly And LLY:US USD 1.64B 29M
Halozyme Therapeutics HALO:US USD 36.35M 2.28M
Immunogen IMGN:US USD 42.06M 8.44M
Insmed INSM:US USD 73.48M 2.1M
Karyopharm Therapeutics KPTI:US USD 34.65M 4K
Macrogenics MGNX:US USD 13.67M 1.68M
Mannkind MNKD:US USD 22.1M 543K
Merk MRK:US USD 2.63B 134M
Minerva Neurosciences NERV:US USD 1.88M 959.93K
Novavax NVAX:US USD 161.66M 38.79M
Novo Nordisk A Fs NVO:US DKK 15.09B 2.48B
Peregrine Pharmaceuticals PPHM:US USD 7.11M 276K
Pfizer PFE:US USD 4.87B 1.33B
Xencor XNCR:US USD 12.75M 377K